Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Comment by CancerSlayeron Aug 13, 2024 8:56am
228 Views
Post# 36176156

RE:RE:RE:RE:SO IM MISSING THE GOOD NEWS

RE:RE:RE:RE:SO IM MISSING THE GOOD NEWS
Indeed...and one should not overlook the fact that there is a general doctor shortage, which is a growing & relatively hidden healthcare crisis.  In the clinic, there are too many docs currently working under a major time crunch.  Any protocol that requires fewer treatments will ultimately enable increased patient access & provide a doc more availability/time to treat another patient.  

As people live longer, the number of specialty/cancer patients will grow & this will simply overextend an already stretched thin/tested healthcare system.  Piling on ever-growing layers of bureaucracy/administrative-clerical tasks for docs creates an even bigger crisis.  

Both docs and patients desperately want/need more efficient & simpler cost-effective options that aren't arriving soon enough.  The FDA should be mindful of the many growing unmet needs...I'm betting my dollars to donuts on this one.


<< Previous
Bullboard Posts
Next >>